Etoposide (VP-16) is a potent inducer of micronuclei in male rat meiosis: spermatid micronucleus test and DNA flow cytometry after etoposide treatment.
The genotoxic and cytotoxic effects of etoposide (VP-16), a topoisomerase II inhibitor, on male rat spermatogenic cells were studied by analysing induction of micronuclei during meiosis. Micronuclei (MN) were scored in early spermatids after different time intervals corresponding to exposure of different stages of meiotic prophase. Etoposide had a strong effect on diplotene-diakinesis I cells harvested 1 day after exposure, and a significant effect also on late pachytene cells harvested 3 days after exposure. The effect at 18 days corresponding to exposure of preleptotene stage of meiosis (S-phase) was weaker but also statistically significant. Adriamycin was used as a positive control in this study. The results indicate a different mechanism of action of etoposide compared with adriamycin and other chemicals studied previously with the spermatid micronucleus test. DNA flow cytometry was carried out to assess cytotoxic damage at the same time intervals (1, 3, and 18 days after treatment) at stages I and VII of the seminiferous epithelial cycle allowing a study of cytotoxicity to different spermatogenic cell stages. Damage of differentiating spermatogonia was observed by a decrease in the cell numbers of the 2C peak 1 and 3 days after treatment and by a reduction of the number of 4C cells (primary spermatocytes) 18 d after etoposide treatment. Adriamycin also killed differentiating spermatogonia. Since the cell population which showed a high induction of MN by etoposide was not reduced in number, the genotoxic effect is remarkable. We conclude that etoposide is a potent inducer of genotoxicity and patients treated with this agent during cancer chemotherapy are at a risk of genetic damage.
Department of Medical Genetics, University of Turku, Finland.
J
J
Lähdetie
A
A
Keiski
A
A
Suutari
J
J
Toppari
D000818:Animals; D002452:Cell Count / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects / Q000235:genetics; D002467:Cell Nucleus / Q000187:drug effects; D004247:DNA / Q000187:drug effects / Q000235:genetics; D004249:DNA Damage / Q000235:genetics; D004317:Doxorubicin / Q000633:toxicity; D005047:Etoposide / Q000633:toxicity*; D005434:Flow Cytometry; D008297:Male; D008540:Meiosis / Q000187:drug effects* / Q000235:genetics; D015162:Micronucleus Tests; D051381:Rats; D017207:Rats, Sprague-Dawley; D013087:Spermatids / Q000166:cytology / Q000187:drug effects*; D013091:Spermatogenesis / Q000187:drug effects; D059005:Topoisomerase II Inhibitors
D059005:Topoisomerase II Inhibitors; D005047:Etoposide; D004317:Doxorubicin; D004247:DNA